Evidence map›Paper›PMID 42856490›Full record

ArticleFrontiers in medicine2026

Regression of severe sclerotic chronic graft-versus-host disease after a second haploidentical hematopoietic stem cell transplantation: a case report.

Rongmu Luo, Qihang Man, Xiaomei Zhang, Hexian Guan, Wenjing Gu, Jingbo Wang

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rongmu LuoDepartment of Hematology, Aerospace Center Hospital, Beijing, China.
Qihang ManDepartment of Hematology, Aerospace Center Hospital, Beijing, China.
Xiaomei ZhangDepartment of Hematology, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China.
Hexian GuanDepartment of Hematology, Aerospace Center Hospital, Beijing, China.
Wenjing GuDepartment of Hematology, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China.
Jingbo WangDepartment of Hematology, Aerospace Center Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sclerotic chronic graft-versus-host disease (Scl-cGVHD) is a disabling fibrotic manifestation of cGVHD and frequently exhibits poor responsiveness to conventional immunosuppressive therapy. Therapeutic options remained limited, particularly in pediatric patients. An 8-year-old boy with relapsed acute myeloid leukemia underwent matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) in January 2021. Four months later, he developed progressive cutaneous cGVHD that evolved into severe Scl-cGVHD, with diffuse skin thickening, painful fissures, ulceration, and multiple joint contractures, loss of independent ambulation, and complete dependence in activities of daily living. Skin biopsy demonstrated extensive dermal fibrosis, collagen deposition, and increased

Indexed as

fibrosisgraft vs. host diseasehaploidenticallocalizedsalvage therapysclerodermatransplantation

Identifiers

PMID42856490
PMCPMC13649392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.